The Clinical Application of 1 HMRS in Cerebral Infarct
Guangyao WU,Junmo SUN,Zhixiong TIAN
DOI: https://doi.org/10.3969/j.issn.1001-9324.2001.03.002
2001-01-01
Abstract:Objective To study the changes of the metabolite with the lapse of time and to evaluate 1 HMRS in cerebral ischemic infarction. Materials and Methods According to the time after the attack, 28 cases with cerebral infarct were divided into four groups: (1) superacute group, ＜6h, n=2; (2) acute group, 6h～2d, n=6; (3) subacute group, 2d～6w, n=12; and (4) chronic group, ＞6w, n=8. The normal side (n=20) was taken as control group. PRESS/TE 135ms CSI and PRESS/TE 135ms single voxel acquisition of bilateral corresponding VOL was made. The ratio of NAA, Cr and Cho of study group to that of control group were measured, so were the values of NAA/Cho, NAA/Cr and Lac/Cho of the same side. Results During the superacute stage (n=2), Lac, NAA, Cho and Cr showed no marked alteration. In acute stage (n=6), Lac was increased, NAA began to decrease, Cr was slightly decreased and Cho was remained unchanged. In subacute stage, Lac was further increased and began to decrease after 2 weeks in 2 cases, NAA continued to low down, Cr was lowed and Cho was slightly decreased. In the chronic stage, NAA and Cr were further decreased, Lac showed could still be detected in 3 cases or couldn't be found in 5 cases. Higher Cho in the margin of the lesion was found in 3 cases after 6 months, lowered Cho in 5 cases compared with the control group. Obvious lipid peak was seen in 3 cases in subacute stage and 2 cases in chronic stage. NAA, Cr and Cho in study group were decreased to 58±15%, 35±26%, and 7±5.8%, respectively. NAA/Cho and NAA/Cr in study group were significantly decreased (P＜0.001). Conclusion Increased Lac and decreased NAA are sensitive and reliable indexes reflecting ischemic injury. 1 HMRS can noninvesively monitor material and energetic metabolism, as well as the physiologic and biochemical changes in cerebral infarction, providing information useful for clinical and therapeutic estimation.